Johnson & Johnson reported positive initial results from its Phase II/III ENERGY trial for IMAAVY (nipocalimab-aahu). The investigational treatment targets warm autoimmune hemolytic anemia (wAIHA), a rare and serious blood disorder.

The study demonstrated a statistically significant and durable improvement in hemoglobin levels compared to a placebo. There are currently no approved therapies for this condition.

Patients currently rely on unapproved treatments such as corticosteroids. These results strengthen J&Jā€™s immunology and rare disease pipeline while potentially creating a new revenue driver.